Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C

被引:104
作者
Longman, RS
Talal, AH
Jacobson, IM
Rice, CM
Albert, ML
机构
[1] Inst Pasteur, F-75724 Paris, France
[2] Rockefeller Univ, New York, NY 10021 USA
[3] Cornell Rockefeller Sloan Kettering Tri Inst MD P, New York, NY USA
[4] New York Presbyterian Hosp, New York, NY USA
[5] INSERM, AV0201, Paris, France
关键词
D O I
10.1086/431523
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Initial reports analyzing dendritic cell (DC) function in patients with hepatitis C virus (HCV) infection have been controversial. Here, we enumerate and characterize the function of circulating myeloid and plasmacytoid DCs. The results show lower percentages of myeloid DCs (0.62 vs. 0.83;) and plasmacytoid DCs (0.11 Pp. 05 vs. 0.34;) in patients with chronic HCV infection than in healthy, non-HCV-infected individuals. Pp. 004 Despite the lower numbers of circulating myeloid DCs present, no phenotypic or functional defects were identified. The lower percentage of plasmacytoid DCs resulted in decreased absolute interferon (IFN)-alpha production; however, when analyzed on a per-cell basis, plasmacytoid DCs from HCV-infected patients generated levels of IFN-alpha equivalent to those generated by DCs from healthy, non-HCV-infected individuals. Contrary to data from previous models (which attributed HCV pathogenesis to defects in the DC compartment), our data reveal functional DC subsets in patients with chronic HCV infection. These results are encouraging for DC-based HCV immunotherapy trials.
引用
收藏
页码:497 / 503
页数:7
相关论文
共 25 条
[11]  
Krug A, 2001, EUR J IMMUNOL, V31, P2154, DOI 10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO
[12]  
2-U
[13]   Lack of phenotypic and functional impairment in dendritic cells from chimpanzees chronically infected with hepatitis C virus [J].
Larsson, M ;
Babcock, E ;
Grakoui, A ;
Shoukry, N ;
Lauer, G ;
Rice, C ;
Walker, C ;
Bhardwaj, N .
JOURNAL OF VIROLOGY, 2004, 78 (12) :6151-6161
[14]   Analysis of successful immune responses in persons infected with hepatitis C virus [J].
Lechner, F ;
Wong, DKH ;
Dunbar, PR ;
Chapman, R ;
Chung, RT ;
Dohrenwend, P ;
Robbins, G ;
Phillips, R ;
Klenerman, P ;
Walker, BD .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (09) :1499-1512
[15]   Presence of functional dendritic cells in patients chronically infected with hepatitis C virus [J].
Longman, RS ;
Talal, AH ;
Jacobson, IM ;
Albert, ML ;
Rice, CM .
BLOOD, 2004, 103 (03) :1026-1029
[16]   Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial [J].
Manns, MP ;
McHutchison, JG ;
Gordon, SC ;
Rustgi, VK ;
Shiffman, M ;
Reindollar, R ;
Goodman, ZD ;
Koury, K ;
Ling, MH ;
Albrecht, JK .
LANCET, 2001, 358 (9286) :958-965
[17]   Protection against persistence of hepatitis C [J].
Mehta, SH ;
Cox, A ;
Hoover, DR ;
Wang, XH ;
Mao, Q ;
Ray, S ;
Strathdee, SA ;
Vlahov, D ;
Thomas, DL .
LANCET, 2002, 359 (9316) :1478-1483
[18]   Decreased interferon-α production and impaired T helper 1 polarization by dendritic cells from patients with chronic hepatitis C [J].
Murakami, H ;
Akbar, SMF ;
Matsui, H ;
Horiike, N ;
Onji, M .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2004, 137 (03) :559-565
[19]   Accumulation of B lymphocytes with a naive, resting phenotype in a subset of hepatitis C patients [J].
Ni, JH ;
Hembrador, E ;
Di Bisceglie, AM ;
Jacobson, IM ;
Talal, AH ;
Butera, D ;
Rice, CM ;
Chambers, TJ ;
Dustin, LB .
JOURNAL OF IMMUNOLOGY, 2003, 170 (06) :3429-3439
[20]   Prostaglandin E2 and tumor necrosis factor alpha cooperate to activate human dendritic cells: Synergistic activation of interleukin 12 production [J].
Rieser, C ;
Bock, G ;
Klocker, H ;
Bartsch, G ;
Thurnher, M .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (09) :1603-1608